From Estrogen Metabolites to Fibrosis: The 16-Hydroxyestrone (16α-OHE1) –TGF-β–mTOR Axis as the Shared Pathway in Lipedema, as Established in other Estrogenic Fibrotic Disorders

Background: Lipedema is a chronic, progressive fibrotic disorder affecting an estimated 11 percent of women, characterized by symmetric adipose deposition predominantly in the lower extremities, disproportionate to the trunk, and accompanied by pain, easy bruising, tissue nodularity, and marked resistance to caloric restriction. Disease onset consistently coincides with hormonal transitions — puberty, pregnancy, and menopause — implicating estrogen metabolism as a central upstream driver. Lipedema frequently co-occurs with hypermobile Ehlers-Danlos Syndrome (hEDS) and mast cell activation syndrome (MCAS), conditions that share connective tissue vulnerability, inflammatory dysregulation, and hormonal sensitivity, suggesting common upstream pathophysiologic mechanisms. Despite growing recognition of vascular abnormalities and extracellular matrix remodeling in lipedema tissue, the biochemical mechanisms linking hormonal triggers to progressive fibrosis — and to the full constellation of clinical symptoms — remain undefined. Surgical intervention, including suction-assisted lipectomy, is frequently warranted to remove painful fibrotic tissue and restore function. However, the biochemical environment driving fibrotic accumulation remains active following surgery in the absence of upstream hormonal and methylation correction, underscoring the need for a mechanistic framework that addresses the pathologic process at its origin.

Objective: This manuscript proposes a unifying pathophysiologic framework in which dysregulated estrogen metabolism — specifically excess production of the proliferative metabolite 16α-hydroxyestrone (16α-OHE1) — activates transforming growth factor-beta (TGF-β) and mechanistic target of rapamycin (mTOR) signaling, driving fibroblast-to-myofibroblast conversion, extracellular matrix accumulation, and self-sustaining fibrotic progression in lipedema. The model further proposes that the same hormonal and inflammatory milieu driving fibrosis also destabilizes connective tissue integrity, promotes mast cell hyperreactivity, and disrupts mitochondrial energy metabolism, providing mechanistic explanations for the characteristic symptoms of lipedema that have not previously been systematically addressed.

Approach: This integrative mechanistic review synthesizes peer-reviewed histologic evidence, endocrine signaling literature, inflammatory pathway data, and genetic polymorphism studies — including MTHFR, MTHFD, and COMT — to examine the CYP1B1–COMT axis as a determinant of metabolite imbalance. The model positions lipedema within a broader class of estrogen-responsive fibrotic disorders in which TGF-β and mTOR activation have been independently characterized, including uterine fibroids, endometriosis, breast cancer stroma, pulmonary fibrosis, and coronary hypertrophy.

Findings: Analysis of the proposed signaling axis reveals three unifying mechanistic themes: TGF-β directly induces active fibrosis through fibroblast-to-myofibroblast conversion and collagen deposition; TGF-β simultaneously suppresses degradation of existing fibrotic matrix through TIMP-mediated inhibition of MMP activity, trapping accumulated extracellular matrix in place; and chronic TGF-β and mTOR activation drives mitochondrial dysfunction, impairing cellular energy metabolism and perpetuating metabolic inflexibility. These three themes operate concurrently and reinforce one another, explaining why lipedema fibrosis is both progressive and treatment-resistant. Nine interdependent, self-sustaining fibrotic loops are identified, integrating hormonal, inflammatory, metabolic, and genetic inputs. These loops converge on a Master Convergence Loop in which upstream estrogen metabolite dysregulation, impaired methylation, and mTOR-driven mitochondrial dysfunction perpetuate fibrosis through TIMP-mediated suppression of MMP activity and progressive extracellular matrix remodeling. Critically, this framework provides mechanistic explanations for the full clinical symptom burden of lipedema: disproportionate pain is accounted for by prostaglandin E2 (PGE-2) sensitization, NMDA receptor activation driven by impaired methylation, and histamine-mediated peripheral nerve hypersensitivity amplified by MCAS. Exercise intolerance and limited cardiac output reflect impaired microvascular perfusion and compromised mitochondrial ATP storage capacity. The poor tolerance of fasting and ketogenic dietary approaches is explained by mitochondrial dysfunction that impairs metabolic flexibility and the capacity to sustain fat oxidation as a primary fuel source. Together, these mechanisms account for lipedema's hormonal sensitivity, characteristic lower-extremity distribution, metabolic inflexibility, and resistance to conventional weight management. The connective tissue fragility of hEDS and the mast cell hyperreactivity of MCAS are further proposed to amplify the fibrotic and inflammatory burden through shared upstream pathways.

Conclusions: The 16α-OHE1/TGF-β–mTOR axis represents a biologically plausible and clinically actionable unifying mechanism for lipedema pathogenesis and its associated conditions. Central to the therapeutic model proposed is the principle that hormonal and estrogen metabolite rebalancing, combined with targeted methylation support, must precede or accompany downstream interventions. Just as impaired methylation allows toxic metabolites to recirculate rather than be cleared, restoring methylation capacity — through methyl donors, COMT and CYP1B1 pathway support, and reduction of proliferative estrogen metabolites — effectively clears the biochemical burden that sustains fibrotic signaling. Therapeutic strategies targeting estrogen metabolite balance, methylation support, TGF-β modulation, and mTOR signaling are discussed in full, with particular relevance for patients presenting with the lipedema–hEDS–MCAS triad. The estrogen metabolite dysregulation proposed as central to lipedema pathogenesis represents the same upstream biochemical vulnerability implicated in uterine fibroids, endometriosis, pulmonary arterial hypertension, hepatic fibrosis, and estrogen receptor–positive breast cancer — conditions that cluster in women with lipedema at rates exceeding coincidence, and whose shared mechanistic origin suggests that lipedema should be recognized as a sentinel condition for broader estrogen-responsive fibrotic disease risk. This framework warrants formal investigation and may inform targeted, evidence-based treatment approaches for this underrecognized and undertreated condition.